BioVersys Reports Results From Phase 2a ENABLE Study

(RTTNews) - BioVersys AG (BIOV.SW) announced results from the Phase 2a ENABLE study of alpibectir in combination with ethionamide or AlpE in patients with newly diagnosed drug-sensitive pulmonary tuberculosis. The phase 2a ENABLE study showed early bactericidal activity in all regimens evaluated over 14 days in patients with newly diagnosed drug-sensitive pulmonary tuberculosis.

Marc Gitzinger, CEO, BioVersys, said: "The results from the Phase 2a ENABLE trial provide important clinical evidence supporting the continued development of AlpE as a potential component of future tuberculosis treatment regimens."

At prior close on SIX Swiss Exchange, BioVersys shares were trading at 22.50 francs.

For More Such Health News, visit rttnews.com.

RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source

Tags

Latest Articles

Data is currently not available